查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085547

法布瑞氏症治療市場：依治療類型、給藥途徑、病患人口統計特徵、治療方法、最終使用者和通路分類－2026-2032年全球市場預測

Fabry Disease Treatment Market by Treatment Type, Route Of Administration, Patient Type, Therapy Approach, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，法布瑞氏症治療市場將成長至 55.9 億美元，複合年成長率為 9.57%。

主要市場統計數據
基準年 2025 29.4億美元
預計年份：2026年 32億美元
預測年份 2032 55.9億美元
複合年成長率 (%) 9.57%

法布瑞氏症治療市場執行摘要

法布瑞氏症是一種罕見的X連鎖溶小體儲積症，由致病性GLA基因突變和α-半乳糖苷酶A缺乏所引起。目前，此病的治療正從對症治療發展到精準醫療。溶小體中Globotriaosylceramide和三己糖鞘氨醇（通常稱為「溶小體-Gb3」）的進行性累積會導致腎臟、心臟、神經系統、皮膚、眼睛和消化器官系統等多個器官併發症，因此早期診斷和器官監測對長期預後至關重要。

法布瑞氏症治療環境的變革性變化

法布瑞氏症的治療正從標準化的酵素替代療法轉向基於基因型、生物標記驅動的器官特異性治療。臨床醫師擴大利用GLA基因突變分析、α-半乳糖苷酶A活性檢測、溶血磷脂酶Gb3監測、腎功能評估、蛋白尿評估、磁振造影（MRI）、超音波心臟超音波圖、神經系統評估和家族級聯篩檢等手段，以便更早識別患者並制定個人化的治療策略。

人工智慧對法布瑞氏症治療的累積影響

人工智慧正逐漸成為法布瑞氏症治療的實用工具，尤其是在早期檢測、優先診斷和協調長期照護方面。人工智慧驅動的電子健康記錄篩檢可以識別不明原因的左心室肥厚、慢性腎臟病、蛋白尿、早期中風、神經性疼痛、血管角化症、少汗症、角化囊腫、胃腸道症狀或家族病史等多種症狀的組合，並可能提示需要進行α-半乳糖苷酶A檢測或GLA定序。

法布瑞氏症治療的關鍵區域見解

北美仍然是法布瑞氏症治療的主要地區，這得益於其完善的罕見疾病中心、專業的藥房基礎設施、基因檢測的普及、新生兒篩檢計畫、臨床試驗活動，以及獲得FDA批准的治療方案，例如酵素替代療法、用於治療特定變異的口服migrastat和pegnigasidase alfa。歐洲的優點包括EMA核准的療法、孤兒藥計畫、專業的溶小體儲積症中心、病患登記系統和跨境臨床專業知識，但治療的可近性和醫療覆蓋時間仍因各國醫療保健體系的不同而有所差異。

來自全球健康聯盟各主要團體的見解

歐盟透過歐洲藥品管理局 (EMA) 的集中監管、孤兒藥體系、國家衛生技術評估、罕見疾病措施以及支持成員國間專家合作的歐洲參考網路，為法布瑞氏症治療提供了最系統化的環境之一。七國集團 (G7) 國家普遍擁有先進的診斷能力、專業的臨床中心、更完善的保險報銷機制、參與臨床試驗的積極性以及真實世界數據 (REW) 基礎設施，為引入治療方法和開展長期療效研究創造了至關重要的環境。

法布瑞氏症治療重點市場的關鍵國家。

美國在法布瑞氏症治療創新方面處於領先地位，這得益於其獲得FDA批准的療法、罕見疾病臨床研究、專業藥房模式、廣泛的基因檢測以及在腎臟病學、循環系統、神經病學、遺傳學和代謝醫學等領域強大的跨學科專業知識。在加拿大，罕見疾病的專業知識和公共保險途徑已相當完善，但各省在治療可及性方面的決策有所不同。墨西哥和巴西的診斷系統和公共部門的醫療服務正在不斷擴展，而巴西在罕見疾病專科中心和相關政策的支持下，已成為拉丁美洲的治療中心。

為法布瑞氏症治療領域的領導者提供的實用建議

產業領導者應優先考慮法布瑞氏症早期診斷，並與腎臟病學、循環系統、神經病學、眼科學、皮膚病學、小兒科和遺傳學等領域的網路合作。家族內級聯篩檢、高風險族群篩檢方案、生物標記教育以及對真實世界數據登記的投資，可以提高患者識別率，同時加強關於腎臟、心臟、神經系統和消化器官系統結局以及生活品質（QOL）的證據。

調查方法與證據框架

本調查方法整合了來自檢驗來源的數據，包括FDA、EMA、NIH、Orphanet、GeneReviews、同行評審期刊、臨床試驗註冊庫、國家罕見疾病政策文件、新生兒篩檢出版物和醫療技術評估資料，此外還參考了已驗證的二級研究、監管資訊來源和臨床指南。此證據架構強調經臨床檢驗的事實，避免做出毫無根據的預測。

結論：法布瑞氏症治療的未來方向

法布瑞氏症的治療已進入一個競爭更加激烈、更加精準、更實證的階段。酵素替代療法仍然是基礎治療手段，而口服藥物米格司他則為合格的患者提供了基於基因型的替代療法。此外，新型生物製藥和臨床實驗療法的出現，也提高了人們對治療便利性、疾病持續控制和器官保護的期望。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 法布瑞氏症治療市場：依治療類型分類

  • Chaperone療法
  • 酵素替代療法
    • 阿加糖酶α
    • 阿加糖酶BETA
  • 基因治療
    • AAV基地
    • 基於慢病毒的
  • 基材減少療法
    • 盧塞拉斯塔特
    • 本克魯斯特

第8章 法布瑞氏症治療市場：依給藥途徑分類

  • 靜脈
  • 口服

第9章：法布瑞氏症治療市場：依患者類型分類

  • 成人
  • 兒童

第10章：法布瑞氏症治療市場：依治療方法分類

  • 根治性的
  • 安寧療護

第11章 法布瑞氏症治療市場：依最終用戶分類

  • 家庭醫療保健
  • 醫院
  • 專科診所

第12章 法布瑞氏症治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 法布瑞氏症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 法布瑞氏症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 法布瑞氏症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • 4D Molecular Therapeutics, Inc.
  • Avrobio, Inc.
  • Bioasis Technologies Inc.
  • BioMarin Pharmaceutical Inc.
  • CANbridge Pharmaceuticals Inc.
  • CellGenTech, Inc.
  • Chiesi Farmaceutici SpA
  • E-Scape Bio, Inc.
  • Freeline Therapeutics Holdings plc
  • Green Cross Corporation
  • Idorsia Pharmaceuticals Ltd.
  • ISU Abxis Co., Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • M6P Therapeutics
  • Nippon Shinyaku Co., Ltd.
  • Protalix BioTherapeutics, Inc.
  • Resolve Therapeutics, LLC
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Zambon SpA
Product Code: MRR-4348D129FB16

The Fabry Disease Treatment Market is projected to grow by USD 5.59 billion at a CAGR of 9.57% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.94 billion
Estimated Year [2026] USD 3.20 billion
Forecast Year [2032] USD 5.59 billion
CAGR (%) 9.57%

Fabry Disease Treatment Executive Summary

Fabry disease treatment is advancing from symptomatic management toward precision therapy for a rare X-linked lysosomal storage disorder caused by pathogenic GLA variants and deficient alpha-galactosidase A activity. Progressive accumulation of globotriaosylceramide and globotriaosylsphingosine, commonly referenced as lyso-Gb3, contributes to renal, cardiac, neurologic, dermatologic, ophthalmic, and gastrointestinal complications, making early diagnosis and organ monitoring central to long-term outcomes.

The current Fabry disease treatment landscape includes enzyme replacement therapy, oral migalastat for patients with amenable GLA variants, and multidisciplinary supportive care for pain, kidney disease, cardiac involvement, stroke prevention, and gastrointestinal symptoms. Regulatory approvals from authorities such as the FDA and EMA, orphan drug frameworks, genetic testing adoption, newborn screening in selected jurisdictions, and specialized rare disease care networks continue to shape patient access, therapeutic differentiation, and evidence generation.

Transformative Shifts in the Fabry Disease Treatment Landscape

The Fabry disease treatment landscape is shifting from standardized enzyme replacement therapy toward genotype-informed, biomarker-guided, and organ-specific care. Clinicians increasingly rely on GLA variant interpretation, alpha-galactosidase A enzyme activity, lyso-Gb3 monitoring, renal function measures, proteinuria assessment, cardiac magnetic resonance imaging, echocardiography, neurologic evaluation, and family cascade screening to identify patients earlier and tailor therapy decisions.

Therapeutic innovation is also broadening. Pegunigalsidase alfa added a newer enzyme replacement option following 2023 approvals in major regulated markets, while migalastat supports oral treatment for eligible patients with amenable variants. Investigational gene therapy, mRNA-based approaches, substrate reduction strategies, pharmacological chaperones, and improved delivery models are reshaping expectations for convenience and disease modification, although long-term durability, immunogenicity, safety, patient selection, and reimbursement evidence remain decisive adoption factors.

Cumulative Impact of Artificial Intelligence on Fabry Disease Care

Artificial intelligence is becoming a practical enabler in Fabry disease treatment, particularly in earlier detection, diagnostic prioritization, and longitudinal care coordination. AI-supported electronic health record screening can flag combinations such as unexplained left ventricular hypertrophy, chronic kidney disease, proteinuria, early stroke, neuropathic pain, angiokeratomas, hypohidrosis, cornea verticillata, gastrointestinal symptoms, or family history that may warrant alpha-galactosidase A testing or GLA sequencing.

AI can also support variant classification, digital pathology review, cardiac imaging interpretation, renal risk stratification, clinical trial matching, pharmacovigilance, and real-world evidence generation. Its cumulative value depends on clinically validated datasets, rare disease-aware model design, bias controls, transparent governance, clinician oversight, and compliance with data privacy regulations because Fabry disease datasets are typically small, heterogeneous, and influenced by delayed diagnosis and under-recognition in female patients.

Key Regional Insights for Fabry Disease Treatment

North America remains a leading region for Fabry disease treatment due to established rare disease centers, specialty pharmacy infrastructure, genetic testing availability, selected newborn screening initiatives, clinical trial activity, and access to FDA-approved treatment options including enzyme replacement therapy, oral migalastat for amenable variants, and pegunigalsidase alfa. Europe benefits from EMA-approved therapies, orphan medicinal product pathways, expert lysosomal storage disorder centers, patient registries, and cross-border clinical expertise, although reimbursement timing and treatment access continue to vary across national health systems.

Asia-Pacific is expanding through improved genetic testing, specialist referral pathways, and rare disease policy development in Japan, China, South Korea, India, and Australia. Japan and Australia have established lysosomal disorder expertise and structured reimbursement mechanisms, while China, India, and Southeast Asian markets are strengthening diagnosis and referral capacity. Latin America shows rising awareness and advocacy, led by Brazil and Mexico, but affordability, infusion infrastructure, and public-sector coverage remain key barriers. The Middle East is advancing through tertiary hospitals, consanguinity-focused genetic programs, and selective public funding, particularly in high-income Gulf countries, while Africa remains constrained by limited diagnostic access, scarce specialist networks, and uneven availability of advanced therapies outside major urban centers.

Key Group Insights Across Global Health Alliances

The European Union provides one of the most structured environments for Fabry disease treatment through centralized EMA oversight, orphan medicinal product pathways, national health technology assessment, rare disease strategies, and European reference networks that support expert collaboration across member states. G7 countries generally demonstrate advanced diagnostic capacity, specialized clinical centers, stronger reimbursement mechanisms, clinical trial participation, and real-world evidence infrastructure, making them important settings for treatment adoption and long-term outcomes research.

BRICS countries are strategically important because of large patient populations, expanding genomics capacity, growing rare disease policy attention, and increasing specialist training, although access remains uneven across income groups and regions. ASEAN markets are improving Fabry disease awareness through specialist education and genetic medicine development, yet reimbursement, enzyme testing access, and specialist density remain constraints. GCC countries benefit from investment in genomic medicine, tertiary hospitals, and inherited disease programs, supporting earlier detection in selected populations. NATO is not a healthcare bloc, but many member countries overlap with advanced rare disease systems in North America and Europe, where regulatory maturity, specialist networks, and reimbursement frameworks support Fabry disease treatment access.

Key Country Insights for Priority Fabry Disease Treatment Markets

The United States anchors Fabry disease treatment innovation through FDA-approved therapies, rare disease clinical research, specialty pharmacy models, broad genetic testing access, and strong multidisciplinary expertise in nephrology, cardiology, neurology, genetics, and metabolic medicine. Canada has established rare disease expertise and public reimbursement pathways, although access decisions vary by province. Mexico and Brazil are expanding diagnosis and public-sector access, with Brazil serving as a major Latin American treatment hub supported by specialist centers and rare disease policy activity.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine specialist lysosomal disorder centers, genetic testing pathways, and reimbursement review processes that guide access to enzyme replacement and genotype-specific therapy, while Russia has more variable access across regions and healthcare settings. China is strengthening rare disease policy, diagnostic capacity, and hospital-based specialist care; India is improving awareness and genetic testing access but faces affordability and reimbursement limitations; Japan has long-standing lysosomal storage disorder expertise and structured treatment pathways; South Korea supports advanced diagnostics and reimbursement review mechanisms; and Australia benefits from specialist networks, national rare disease planning, and public reimbursement mechanisms for eligible patients.

Actionable Recommendations for Fabry Disease Treatment Leaders

Industry leaders should prioritize earlier Fabry disease diagnosis by partnering with nephrology, cardiology, neurology, ophthalmology, dermatology, pediatrics, and genetics networks. Investment in family cascade screening, high-risk screening protocols, biomarker education, and real-world data registries can improve patient identification while strengthening evidence for renal, cardiac, neurologic, gastrointestinal, and quality-of-life outcomes.

Commercial and medical strategies should reflect therapy eligibility, GLA variant amenability, infusion burden, home infusion feasibility, oral treatment suitability, immunogenicity considerations, adherence, and payer expectations for durable clinical benefit. Stakeholders should build evidence dossiers around validated endpoints, patient-reported outcomes, long-term organ protection, safety surveillance, and comparative real-world evidence. Responsible AI deployment, inclusive trial recruitment, post-marketing monitoring, and region-specific access models should be embedded into product strategy to improve patient outcomes and strengthen healthcare system value.

Research Methodology and Evidence Framework

The research methodology integrates verified secondary research, regulatory intelligence, clinical guideline review, and triangulation of data from authoritative sources such as the FDA, EMA, NIH, Orphanet, GeneReviews, peer-reviewed journals, clinical trial registries, national rare disease policy documents, newborn screening publications, and health technology assessment materials. The evidence framework emphasizes clinically validated facts and avoids unsupported projections.

Analysis focuses on approved therapies, investigational mechanisms, diagnostic pathways, biomarker use, treatment eligibility, regional reimbursement dynamics, access barriers, specialist referral patterns, and stakeholder behavior. Findings are validated through cross-comparison of regulatory labels, clinical evidence, epidemiology literature, patient registry insights, and real-world treatment patterns to ensure that the executive summary remains evidence-based, current, and relevant to industry decision-making in Fabry disease treatment.

Conclusion: Future Direction for Fabry Disease Treatment

Fabry disease treatment is entering a more competitive, precision-driven, and evidence-intensive phase. Enzyme replacement therapy remains foundational, oral migalastat provides a genotype-specific alternative for eligible patients, and newer biologic and investigational approaches are raising expectations for treatment convenience, durable disease control, and organ protection.

Future progress will depend on earlier diagnosis, equitable reimbursement, validated biomarker use, multidisciplinary care, and credible long-term outcomes evidence. Stakeholders that combine scientific rigor, patient-centric access models, responsible AI adoption, robust pharmacovigilance, and region-specific execution will be well positioned in the evolving Fabry disease treatment landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Fabry Disease Treatment Market, by Treatment Type

  • 7.1. Chaperone Therapy
  • 7.2. Enzyme Replacement Therapy
    • 7.2.1. Agalsidase Alfa
    • 7.2.2. Agalsidase Beta
  • 7.3. Gene Therapy
    • 7.3.1. Aav Based
    • 7.3.2. Lentiviral Based
  • 7.4. Substrate Reduction Therapy
    • 7.4.1. Lucerastat
    • 7.4.2. Venglustat

8. Fabry Disease Treatment Market, by Route Of Administration

  • 8.1. Intravenous
  • 8.2. Oral

9. Fabry Disease Treatment Market, by Patient Type

  • 9.1. Adult
  • 9.2. Pediatric

10. Fabry Disease Treatment Market, by Therapy Approach

  • 10.1. Curative
  • 10.2. Palliative

11. Fabry Disease Treatment Market, by End User

  • 11.1. Home Healthcare
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Fabry Disease Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Fabry Disease Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Fabry Disease Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Fabry Disease Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. 4D Molecular Therapeutics, Inc.
  • 17.2. Avrobio, Inc.
  • 17.3. Bioasis Technologies Inc.
  • 17.4. BioMarin Pharmaceutical Inc.
  • 17.5. CANbridge Pharmaceuticals Inc.
  • 17.6. CellGenTech, Inc.
  • 17.7. Chiesi Farmaceutici S.p.A.
  • 17.8. E-Scape Bio, Inc.
  • 17.9. Freeline Therapeutics Holdings plc
  • 17.10. Green Cross Corporation
  • 17.11. Idorsia Pharmaceuticals Ltd.
  • 17.12. ISU Abxis Co., Ltd.
  • 17.13. JCR Pharmaceuticals Co., Ltd.
  • 17.14. M6P Therapeutics
  • 17.15. Nippon Shinyaku Co., Ltd.
  • 17.16. Protalix BioTherapeutics, Inc.
  • 17.17. Resolve Therapeutics, LLC
  • 17.18. Sangamo Therapeutics, Inc.
  • 17.19. Sanofi S.A.
  • 17.20. Swedish Orphan Biovitrum AB
  • 17.21. Takeda Pharmaceutical Company Limited
  • 17.22. Zambon S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FABRY DISEASE TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL FABRY DISEASE TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL FABRY DISEASE TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL FABRY DISEASE TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL FABRY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL FABRY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHAPERONE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHAPERONE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHAPERONE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AGALSIDASE ALFA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AGALSIDASE ALFA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AGALSIDASE ALFA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AGALSIDASE BETA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AGALSIDASE BETA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AGALSIDASE BETA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AAV BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AAV BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AAV BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LENTIVIRAL BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LENTIVIRAL BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LENTIVIRAL BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SUBSTRATE REDUCTION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SUBSTRATE REDUCTION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SUBSTRATE REDUCTION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUCERASTAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LUCERASTAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUCERASTAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VENGLUSTAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VENGLUSTAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VENGLUSTAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CURATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CURATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CURATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PALLIATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PALLIATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PALLIATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 154. GCC FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GCC FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. G7 FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. G7 FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 184. G7 FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. NATO FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 194. NATO FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. INDIA FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 310. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 311. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 320. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 321. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 322. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 327. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 330. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 331. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 332. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 337. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 338. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 340. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 341. SOUTH KOREA FABRY DISEASE TREATMENT M